8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A complete guide to pioglitazone's FDA approval history, compounding legal status, label requirements, and post-market safety data. Reviewed by the HealthRX medical team.
A detailed comparison of how the FDA and EMA have regulated pioglitazone (Actos), including label differences, bladder cancer warnings, cardiovascular data, and post-market safety decisions.
A clinical review of pioglitazone (Actos) FDA Adverse Event Reporting System signals, including bladder cancer risk, heart failure, fractures, and macular edema, with regulatory timeline and current label warnings.
Complete FDA approval history of pioglitazone (Actos), including original 1999 approval, black box warnings, bladder cancer reviews, and current prescribing label status.
A detailed review of pioglitazone's regulatory history across the FDA, EMA, and other global agencies, including approval timelines, label changes, safety communications, and current prescribing status.
A detailed review of every FDA label change for pioglitazone (Actos) from 2020 through 2026, including updated bladder cancer language, heart failure warnings, bone fracture data, and NASH-related off-label use considerations.
A complete clinical and regulatory guide to pioglitazone (Actos): FDA approval timeline, patent litigation, label updates, post-market safety findings, and what the evidence means for prescribers and patients.
A clinical review of pioglitazone's FDA approval history, current label, post-market safety surveillance, and the next-generation thiazolidinedione pipeline including MSDC-0602K and seladelpar.